OmniAb Earnings Call Highlights Surge In Milestones

Omniab, Inc. ((OABI)) has held its Q1 earnings call. Read on for the main highlights of the call.

OmniAb’s latest earnings call struck an upbeat tone as management highlighted a sharp revenue surge, meaningful clinical progress and tighter cost controls that together prompted a raise in full‑year guidance. Executives acknowledged ongoing net losses, reliance on milestone payments and a projected cash drawdown, but argued that a deep partnered pipeline and expanding technology adoption provide growing visibility into future economics.

Explosive Revenue Growth on Partner Milestones

OmniAb reported first‑quarter 2026 revenue of $14.4 million, up from $4.2 million a year earlier, representing about 243% growth driven largely by milestone payments from partners. Management emphasized that this jump reflects tangible clinical advancement across the portfolio rather than one‑off deals, underscoring the leverage in its collaboration model.

Full‑Year 2026 Outlook Raised After Strong Start

On the back of the strong first quarter, the company lifted its 2026 revenue guidance to a range of $28 million to $33 million, up from prior expectations. Leaders said an unexpected milestone in the quarter improved their line of sight on potential upside, though they stressed that the pace and timing of future milestones remain inherently variable.

Clinical Pipeline Gains Critical Mass

The platform’s clinical footprint continued to expand, with 32 active clinical or approved programs and two OmnidAb‑derived candidates entering human trials in the quarter, including one that has already progressed to Phase II. Notably, the antibody Ramantamig advanced from Phase I into Phase III, contributing to roughly $350 million of remaining potential contracted milestones tied to clinical‑stage assets.

Multi‑Billion‑Dollar Milestone and Royalty Opportunity

Across its broader portfolio, OmniAb now counts more than $3.0 billion in total contracted milestones, with an average contracted royalty rate of about 3.4%. Management highlighted that roughly 98% of active programs carry some form of future economic participation for OmniAb, creating a large, diversified base of potential long‑term revenue streams.

Operating Costs Trend Lower on Efficiency Push

GAAP operating expenses edged down to $22.3 million from $23.0 million in the prior‑year quarter as the company trimmed spending in key areas. Research and development expenses fell to $9.6 million and general and administrative costs declined to $6.6 million, while a new cash operating expense metric showed an even steeper drop once noncash items were stripped out.

Loss Narrows as Profitability Metrics Improve

OmniAb’s net loss shrank to $7.7 million, or $0.06 per share, versus a loss of $18.2 million, or $0.17 per share, a year earlier, marking roughly a 58% improvement. Excluding the one‑time noncash charge booked in the quarter, the loss would have been about $0.04 per share, underscoring a trend toward better operating leverage even as the company remains in the red.

Cash Cushion Supports Near‑Term Operations

The company closed the quarter with $49.1 million in cash and equivalents, giving it what management described as a solid near‑term runway. With revenue expectations raised and cash operating expense guidance unchanged, OmniAb now anticipates finishing the year with between $33 million and $38 million of cash on the balance sheet.

Technology Platforms Gain Commercial Traction

OmniAb reported growing commercial momentum for its xPloration single B‑cell platform, which is building a broader sales funnel through demonstrations and new evaluations. The recently launched OmniUltra offering and the OmnidAb technology, which already has programs in the clinic, are gaining adoption among partners that include eight of the world’s top ten pharmaceutical companies.

One‑Time Noncash Impairment Weighs on GAAP

During the quarter, OmniAb recorded a $2.9 million noncash write‑off tied to legacy small‑molecule ion channel intangible assets, which pushed reported GAAP operating expenses higher. This impairment also drove an increase in full‑year GAAP operating expense guidance to $83 million to $88 million, a move executives said masks the underlying improvement in cash‑based spending.

Revenue and Program Activity Remain Lumpy

Management cautioned that the company’s revenue is still primarily driven by milestones, making quarterly results inherently uneven despite the strong first quarter. They also pointed to lumpiness in new program starts and normal attrition in the pipeline, while acknowledging that broader early‑stage biotech headwinds could intermittently weigh on preclinical activity.

Continuing Losses and Funding Sensitivity

Even with improved metrics, OmniAb remains unprofitable and expects its cash balance to decline from current levels by year‑end, reflecting ongoing cash burn. Leadership framed this as a manageable trajectory given current resources but noted that the business remains sensitive to the pace of milestone receipts and longer‑term funding needs.

Royalties Still in the Future

While the company’s royalty contracts represent a major potential upside, management conceded that near‑term revenue is still dominated by milestones rather than ongoing royalties. They expect royalty contributions to become more meaningful only as partnered programs reach commercialization over time, a process whose timing remains uncertain and dependent on partner execution.

Guidance Underscores Confidence in Partnered Model

Looking ahead, OmniAb’s raised 2026 revenue outlook of $28 million to $33 million signals growing confidence in its partner‑driven model, supported by 107 active partners and 409 active programs. The company reiterated GAAP operating expense guidance of $83 million to $88 million, maintained cash operating expense expectations of $50 million to $55 million, and projected year‑end cash of $33 million to $38 million alongside a minimal effective tax rate.

OmniAb’s earnings call painted the picture of a platform company hitting its stride, with surging milestone revenue, a deepening clinical pipeline and disciplined cost control translating into a sharply narrower loss. Investors will need to balance that momentum against the inherent volatility of milestone‑based revenue and the ongoing march toward profitability, but for now the trajectory appears firmly pointed upward.